MABp1

Drug Profile

MABp1

Alternative Names: CA-18C3; CV-18C3; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 10 Dec 2016

Price : $50

At a glance

  • Originator XBiotech
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Colorectal cancer; Vascular restenosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • Phase I Haematological malignancies

Most Recent Events

  • 07 Dec 2016 XBiotech completes enrolment in the phase III XCITE trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in 18 countries worldwide, including USA, Poland, Hungary, Belgium, Czech Republic, Spain, Austria, Germany, Netherlands, and United Kingdom (IV) , (NCT01767857), (EudraCT2012-005287-10)
  • 02 Jul 2016 Efficacy and adverse events data from a phase III trial in Colorectal cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016) and 18th World Congress on Gastrointestinal Cancer (WCGC-2016)
  • 28 Jun 2016 XBiotech and Megapharm enter into a licensing agreement to commercialise MABp1 in Israel for Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top